MedTrace Logo

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

NCT06910384 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-12-18

No results posted yet for this study

Summary

This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.

Conditions

Interventions

BIOLOGICAL

STR04

autologous bone-marrow-derived mesenchymal stem cells

Sponsors & Collaborators

  • New England Cell Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan Jacobs, MD, PhD · New England Cell Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2025-12-16
Completion
2025-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06910384 on ClinicalTrials.gov